Serum nitric oxide products in patients with multiple sclerosis: relationship with clinical activity

dc.creatorZabaleta, Mercedes E.
dc.creatorBianco Colmenares, Nicolás E.
dc.creatorDe Sanctis, Juan B.
dc.date2017-03-06T14:33:00Z
dc.date2017-03-06T14:33:00Z
dc.date1998
dc.date.accessioned2022-10-28T01:22:07Z
dc.date.available2022-10-28T01:22:07Z
dc.identifier0269-8951
dc.identifierhttp://hdl.handle.net/10872/14833
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4948411
dc.descriptionWe have assessed nitric oxide (NO) products, nitrites and nitrates in the sera of 80 controls and 14 patients with multiple sclerosis (MS) in different stages of clinical activity: seven with clinical remission (RR) (clinically inactive) and seven with chronic progressive (CP) disease (four active and three inactive). Overall, the levels of nitrites, nitrates and total NO products were significantly lower (p < 0.001) in MS patients than in controls. However, this decrease was significant only in patients with RR (P < 0.0001) and inactive CP (P < 0.0005). Likewise, patients with RR and inactive CP patients had significantly (P < 0.00 1 and P < 0.05 respectively) lower levels of NO products (16.92 ± 3.1 μmol/l and 18 ± 3.17 μmol/l respectively) as compared to active CP patients (24.1 ± 2.81 μmol/l). Serum NO levels may vary with the stage and activity of the disease. Future studies should ascertain the importance of serum NO in MS.
dc.languageen
dc.publisherMedical science research
dc.relationVol. 26;pp. 373-374
dc.subjectnitric oxide
dc.subjectmultiple sclerosis
dc.subjectnitrite
dc.subjectnitrate
dc.titleSerum nitric oxide products in patients with multiple sclerosis: relationship with clinical activity
dc.typeArticle


Este ítem pertenece a la siguiente institución